Pink Sheet reports on Aranesp and Procrit concerns

Members of the FDA's Oncologic Drugs Advisory Committee expressed concerns at a May meeting that DTC advertising of Amgen's Aranesp and Johnson & Johnson's Procrit have given patients a lopsided impression of the drugs' risk/benefit profile, The Pink Sheet reported. The state of New York subpoenaed Aranesp promotional materials that month.
You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.